Related Experiment Videos
[Hypercalcemia in malignancy]
11st Depatment of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushi.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|September 1, 1994
Summary
Malignancy-associated hypercalcemia (MAHC) is a serious complication of cancer, potentially fatal if untreated. Early recognition of symptoms like thirst and polydipsia is crucial for timely diagnosis and management of this condition.
Area of Science:
- Oncology
- Endocrinology
- Pathophysiology
Context:
- Malignant tumors frequently complicate with hypercalcemia, known as malignancy-associated hypercalcemia (MAHC).
- MAHC can lead to severe clinical symptoms and mortality, yet awareness among physicians caring for cancer patients is often low.
- Hypercalcemia affects approximately 15% of solid tumor patients and is more prevalent in hematological malignancies, reaching up to 80% in adult T-cell leukemia.
Purpose:
- To highlight the clinical significance and diagnostic challenges of malignancy-associated hypercalcemia (MAHC).
- To emphasize the importance of recognizing specific symptoms indicative of MAHC.
- To explain the underlying mechanism of MAHC.
Summary:
- MAHC presents with symptoms like anorexia, fatigue, nausea, and vomiting, often mistaken for treatment side effects or disease progression.
- Abnormal thirst and polydipsia are highly characteristic of MAHC, warranting prompt diagnostic consideration.
- Central nervous system symptoms such as emotional lability and somnolence can be life-threatening if MAHC is untreated.
- MAHC is primarily caused by tumor-secreted bone resorption stimulating factor (BRSF), leading to increased bone resorption and elevated serum calcium levels, termed humoral hypercalcemia of malignancy (HHM).
- In multiple myeloma and bone metastases, BRSF drives hypercalcemia through local osteolysis.
Impact:
- Increased physician awareness of MAHC symptoms can improve early diagnosis and patient outcomes.
- Monitoring corrected serum calcium levels is vital for detecting MAHC in patients with malignant diseases.
- Understanding the role of BRSF in MAHC pathogenesis provides targets for future therapeutic strategies.